Investigational drug · Phase 2
BB102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BB102"
First trial start
2025
Dec 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BB102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BB102" as an intervention, largest first.
Broadenbio Ltd., Co.Industry
NCT06258408 · 78 participants (planned) · Start Dec 29, 2022 · Primary completion Dec 2026
Drug: BB102 tablet · For: Advanced Solid Tumor
Sites: Guangzhou, China; Zhengzhou, China
- A Phase 2 Study of BB102 in Patients With Hepatocellular CarcinomaNot yet recruiting
Broadenbio Ltd., Co.Industry
NCT07239986 · 60 participants (planned) · Start Dec 2025 · Primary completion Jun 2027
Drug: BB102 · For: Hepatocellular Carcinoma (HCC)
Sites: Hefei, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Recombinant adenoviral vector expressing human wild-type p53, GM-CSF, and B7-1 genes suppresses the growth of glioma in vivo.
Feng S, Han S, Pan D, et al. · Tumour Biol 2014
- Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells.
Pan D, Wei X, Liu M, et al. · Neurol Res 2010
- Serum antibody levels against select bacterial pathogens in Atlantic bottlenose dolphins, Tursiops truncatus, from Beaufort NC USA and Charleston Harbor, Charleston, SC, USA.
Beck BM, Rice CD · Mar Environ Res 2003
- Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro.
Shi M, Wang FS, Wu ZZ · World J Gastroenterol 2003
- [Adenovirus-mediated transfer of human wild-type p53, GM-CSF, and B7-1 genes efficiently produces growth suppression and apoptosis of hepatocellular cells in vitro].
Shi M, Wang F, Liu M, et al. · Zhonghua Gan Zang Bing Za Zhi 2001
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.